Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

Immune checkpoint blockade (ICB) therapies, which potentiate the body’s natural immune response against tumor cells, have shown immense promise in the treatment of various cancers. Currently, tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are the primary biomarkers ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Conway, Jake R., Kofman, Eric, Mo, Shirley S., Elmarakeby, Haitham, Van Allen, Eliezer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264032/
https://www.ncbi.nlm.nih.gov/pubmed/30497521
http://dx.doi.org/10.1186/s13073-018-0605-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264032/
https://www.ncbi.nlm.nih.gov/pubmed/30497521
http://dx.doi.org/10.1186/s13073-018-0605-7

Ejemplares similares